Noda A, Kamiya N, Takayama T, Hayakawa T
Arch Intern Med. 1977 Jun;137(6):754-60. doi: 10.1001/archinte.137.6.754.
The pancreatic excretion test with a weak acid of 5, 5-dimethyl-2,4-oxazolidinedione (DMO) was performed concomitantly with the pancreozymin-secretin test in 28 patients with pancreatolithiasis, 14 patients with pancreatic carcinoma, and 67 healthy subjects. The DMO concentration and total output of duodenal content after secretin stimulation, when corrected to the simultaneously determined plasma DMO concentration, were significantly reduced in the patients. While the pancreozymin-secretin test was abnormal in 96% of patients with pancreatolithiasis and in 86% of those with pancreatic carcinoma, the pancreatic DMO excretion test gave abnormal results in 100% of the patients. This suggests that the new test may well become effective in detecting early stages of pancreatic disease including carcinoma and chronic pancreatitis.
对28例胰腺结石病患者、14例胰腺癌患者和67名健康受试者同时进行了用5,5 - 二甲基 - 2,4 - 恶唑烷二酮（DMO）这种弱酸进行的胰腺排泄试验以及促胰液素 - 促胰酶素试验。在促胰液素刺激后，经校正至同时测定的血浆DMO浓度后，患者十二指肠内容物的DMO浓度和总排出量显著降低。虽然促胰液素 - 促胰酶素试验在96%的胰腺结石病患者和86%的胰腺癌患者中结果异常，但胰腺DMO排泄试验在100%的患者中结果异常。这表明这项新试验在检测包括癌症和慢性胰腺炎在内的胰腺疾病早期阶段可能会很有效。
